NOVEMBER BDI-40 DOWN 10%; MACQUARIE REPORT HITS MESOBLAST 17%
December 1st 2011 23:35
Biotech Daily
Thursday December 1, 2011
Daily news on ASX-listed biotechnology companies
Thursday December 1, 2011
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
November BDI-40 Down 10%, ASX200 Down 4%
Macquarie Report Hits Mesoblast 17%, BDI-40 6%
Antisense Up 180%, Psivida Down 68%
BIOTECH DAILY’S TOP 40 INDEX
Most of the Biotech Daily Top 20 Index (BDI-20) companies fell in the month of November, but it might have been a different story if we used tonight’s data rather than last night’s end of the month reference point – but that’s statistics for you.
The exceptions were Alchemia and Bionomics, both recovering from earlier falls, Starpharma with a new major investor and Nanosonics looked good by not falling.
The Biotech Daily Top 40 Index (BDI-40) fell 9.7 percent in November with the S&P ASX200 down 4.1 percent for the month. While the ASX began to close the chasm over 12 months, the BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) remained well ahead of the benchmark index for the year to November 30, 2011, up 9.25 percent compared to the ASX200 falling 10.1 percent (see chart below).
A total of 29 companies fell in November with nine up and two unchanged.
Antisense was the clear winner, up 180 percent to a market capitalization of $28 million, as the day-traders ramped the expectation of impending trial results for its growth hormone receptor-targeting drug ATL1103 by the end of this year. Bionomics was up 23.1 percent to $176 million, followed by Anteo (21.3%), Alchemia (18.5%), Optiscan (10%), Compumedics (7.7%), Reva (3.4%) and Nanosonics (0.8%).
Mesoblast’s 16.8 percent or $386 million fall – at the hands of an incorrect but widely disseminated Macquarie Bank report - wiped 6.2 percent from the BDI-40. The biggest percentage fall was Psivida’s 68.2 percent drop to $27 million, triggered by an FDA refusal for its Iluvien drug delivery device. From a low base, Uscom lost 37.5 percent to $5 million and Tissue Therapies’ not-quite-a-licence wounded the company 30 percent to $70 million, followed by Patrys (28.6%), Benitec (26.3%), Genera (20.0%), Living Cell (18.2%), Mesoblast (16.8%), Acrux (16.3%) and Genetic Technologies (15.9%).
CSL climbed 8.1 percent to $16,377 million pushing the three Big Caps up a collective 3.6 percent, despite Cochlear and Resmed both falling more than five percent in November, but for the year, the Big Caps were down 18.0 percent.
BDI-40 v ASX200 Jun 30, 2006 To Nov 30, 2011
BDI-40 v ASX200 Oct 31, 2010 To Nov 30, 2011
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 14 |
| Vote |
Add To: 
subscribe to this blog